TRYP Therapeutics

Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications.  Tryp is on the cusp of initiating four Phase 2a clinical trials using synthetic psilocybin for fibromyalgia, phantom limb pain, complex regional pain syndrome (CRPS), and certain overeating disorders representing more than $12 billion in potential annual sales potential.  The company‚Äôs Scientific Advisory Board is chaired by Robin Carhart-Harris, one of the most prominent psychedelic researchers in the world.